Axogen to Acquire BioCircuit Technologies for $200M, Funds Deal with $208.7M Equity Offering
AXGN has more than doubled off its 52-week low of $15.27.
Summary
Axogen agreed to acquire BioCircuit Technologies for $200M in cash, funded by a $208.7M public offering at $42.50/share. The deal adds NerveTape, the first FDA-cleared sutureless nerve repair device, and is expected to close in Q4 2026.
Key Events · M&A and Partnerships · AXGN
-
$200M BioCircuit Acquisition
Axogen entered into a definitive merger agreement to acquire BioCircuit Technologies for $200 million in cash, subject to customary adjustments. BioCircuit's NerveTape is the first FDA-cleared sutureless device for peripheral nerve repair.
-
$208.7M Equity Offering Priced
Axogen priced 4,910,000 shares at $42.50 per share for gross proceeds of approximately $208.7 million, with a 30-day underwriter option for up to 736,500 additional shares. Underwriters include BofA Securities, Jefferies, and Wells Fargo Securities.
-
Accretive Financial Impact Expected
Management expects the acquisition to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year following closing, while Axogen remains free cash flow positive. BioCircuit had ~$24M run-rate revenue (Q2 2026 annualized) and ~80% gross margins.
-
Q4 2026 Closing Timeline
Closing is expected in Q4 2026, subject to conditions including conversion of BioCircuit's convertible notes, consent under an inbound IP license, and spin-out of BioCircuit's electronics R&D business. Either party may terminate if the merger is not completed by December 31, 2026.
Analysis · AXGN · Industrial Applications And Services
Axogen is making its largest strategic move in years: a $200 million cash acquisition of BioCircuit Technologies, the maker of NerveTape — the first FDA-cleared sutureless device for peripheral nerve repair. The deal is funded almost entirely by a $208.7 million public offering priced at $42.50 per share, representing roughly 8% dilution to existing shareholders. The acquisition expands Axogen's addressable market within its core nerve repair franchise and is expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in year one. The transaction is not conditioned on financing, but Axogen must secure funding within 90 days — a condition it is already satisfying via the concurrent offering. Closing is expected in Q4 2026, subject to BioCircuit's electronics business spin-out and other customary conditions.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXGN was trading at $46.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $15.27 to $52.91. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.